GlassScriptPhysician profile
Stefanie J Schluender
NPI 1871667147
$5,786.55
in general payments reported to CMS, 2019-2025
22 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $553 · 2021: $34.33 · 2022: $124 · 2023: $4,375 · 2024: $215 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $819.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,751.77 | 2020-2024 | Da Vinci Surgical System |
| Amgen INC. | $260.69 | 2019-2022 | |
| Coloplast Corp | $127.33 | 2019-2023 | Sensura Mio |
| Solventum Corporation | $86.45 | 2024-2025 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Incyte Corporation | $64.15 | 2022-2024 | Jakafi |
| Blueprint Medicines Corporation | $63.17 | 2023-2025 | Ayvakit |
| Davol INC. | $62.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.32 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.65 | 2024 | Alunbrig |
| Novartis Pharmaceuticals Corporation | $28.38 | 2025 | |
| Beone Medicines USA, INC. | $28.11 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $27.61 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $26.18 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.74 | 2025 | |
| Myovant Sciences INC. | $19.67 | 2021 | |
| Covidien LP | $19.67 | 2019 | |
| Pfizer INC. | $16.82 | 2024 | |
| Baxter Healthcare | $16.80 | 2024 | Tisseel |
| Medtronic, INC. | $14.67 | 2023 | Signia |
| Lilly USA, LLC | $14.45 | 2023 | Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Schluender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.